Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × olaparib × Breast × Clear all

Phase

Phase 2 38 Phase 1 25 Phase 1/2 11 Phase 3 5 Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2 Breast 1

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

Capecitabine 16 Paclitaxel 15 Docetaxel 13 Cyclophosphamide 11 Carboplatin 11 Epirubicin 9 Trastuzumab 8 Letrozole 8 Gemcitabine 8 Doxorubicin 7 pertuzumab 5 Vinorelbine 4 Cisplatin 4 130-nm albumin-bound paclitaxel 4 exemestane 3 Tamoxifen 3 Lapatinib 3 AC protocol 3 pyrotinib 2 palbociclib 2 camrelizumab 2 Zoledronic Acid 2 Thiotepa 2 Taxes 2 Neoadjuvant Therapy 2 Melatonin 2 Goserelin 2 Fulvestrant 2 Fluorouracil 2 Exercise 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03150576 2022-11-14

PARTNER

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡